Houston, TX – According to filings with the U.S. Securities and Exchange Commission, Ictero Medical is raising $6,148,111.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Matthew Nojoomi played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Ictero Medical
At Ictero Medical, we have developed the first definitive and truly minimally-invasive solution to treat gallstone disease. Our technology provides the benefit of surgical removal of the gallbladder, without the risk. Born out of the Texas Medical Center (TMC) Biodesign fellowship, Ictero is a team of passionate engineers, scientists, clinicians, and entrepreneurs dedicated to developing innovative medical technology that addresses todays most pressing clinical needs. Ictero methodically developed The CholeSafe System to be a commercially viable, definitive, and safe treatment for gallstone disease.

To learn more about Ictero Medical, visit http://icteromedical.com/

Contact:
Matthew Nojoomi, Chief Executive Officer
415-273-9648
https://www.linkedin.com/in/matthew-nojoomi-356349b9/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved